Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

February 26th 2024


A phase 1/2 study found that using azacitidine, venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia yielded high rates of complete response and complete response with incomplete hematologic recovery.